Acquired Company

Lilly completed its acquisition of Adverum Biotechnologies, Inc. on December 9, 2025, paying $3.56 per share in cash plus a contingent value right up to $8.91 per share.

Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops candidate gene therapy products to treat eye and rare diseases. The company is headquartered in Redwood City, California. Show more

100 CARDINAL WAY, REDWOOD CITY, CA, UNITED STATES, 94063, Redwood City, CA, 94063, USA

https://adverum.com

BIOTECHNOLOGY

HEALTHCARE

Start AI Chat

Market Cap

96.26M

52 Wk Range

$1.78 - $5.75

Previous Close

$4.36

Open

$4.36

Volume

N/A

Day Range

$4.36 - $4.36

Enterprise Value

159.1M

Cash

26.06M

Avg Qtr Burn

-28.12M

Insider Ownership

13.21%

Institutional Own.

88.31%

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Ixoberogene soroparvovec (Ixo-vec) (ADVM-022) (AAV.7m8-aflibercept) Details Wet age-related macular degeneration , Age-related macular degeneration, Eye disease	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ADVM-022 (AAV.7m8 Afiblercept) Details Diabetes, Eye disease , Diabetic macular edema	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.